Zygomycosis: the re-emerging fungal infection. (2006 study) Skip to main content
Review European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2006

Zygomycosis: the re-emerging fungal infection.

Chayakulkeeree M, Ghannoum MA, Perfect JR, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2006

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The authors reviewed what is known about zygomycosis, a fungal infection, including its causes, risk factors, forms of disease and treatment.

What They Found

This review article reports that infections caused by Zygomycetes have risen significantly over the past decade, mainly in people with weakened immune systems. Patients with diabetes, cancer, solid organ or bone marrow transplants, or iron overload are at highest risk, as are those taking immunosuppressive drugs, deferoxamine, or broad-spectrum antibiotics. The disease can range from a superficial infection to an angioinvasive infection with high mortality. The review describes a three-part treatment strategy: antifungal drugs, surgery, and control of underlying diseases. Lipid formulations of amphotericin B are the antifungal agents of choice, and posaconazole may become approved for treatment. The clinical experience with colony-stimulating factors, interferon-gamma, and hyperbaric oxygen therapy is still limited.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This is a narrative review rather than a trial, and the abstract reports no data on hyperbaric oxygen outcomes, so it cannot show whether HBOT changes results for patients.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Infection
Source Pubmed
PubMed ID 16568297
Year Published 2006
Journal European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
MeSH Terms Amphotericin B; Antifungal Agents; Communicable Diseases, Emerging; Comorbidity; Drug Resistance, Fungal; Fungi; Humans; Mucormycosis; Risk Factors; Zygomycosis

Cite This Study

Share

Find a Canadian Clinic

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology